Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3493269 - SC
LY3493269 · 1 trial · 1 indication
TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that, at any dose: 1. Results in death 2. Is life-threatening 3. Requires inpatient hospitalization or prolongation of existing hospitalization 4. Results in persistent disability/incapacity 5. Is a congenital anomaly/birth defect 6. Other situations: Based on medical or scientific judgement. A summary of SAEs, TEAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| 1.5 milligrams (mg) Dulaglutide | ACTIVE_COMPARATOR | Participants received 1.5 mg dulaglutide subcutaneously (SC) once weekly (QW) for 4 weeks. |
| 0.3 mg LY3493269 | EXPERIMENTAL | Participants received 4 fixed dosed of 0.3 mg LY3493269 SC QW for 4 weeks. |
| 1 mg LY3493269 | EXPERIMENTAL | Participants received 4 fixed dosed of 1 mg LY3493269 SC QW for 4 weeks. |
| 0.75/1.5/3 mg LY3493269 | EXPERIMENTAL | Participants received LY3493269 0.75 mg on week 1, 1.5 mg on week 2 and 3 mg on week 3 and 4 SC as weekly doses. |
| 1.5/3/4/5 mg LY3493269 | EXPERIMENTAL | Participants received LY3493269 1.5 mg on week 1, 3 mg on week 2, 4 mg on week 3 and 5 mg on week 4 as weekly doses. |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo subcutaneously (SC) once weekly (QW) for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3493269 | DRUG | Administered SC |
| Dulaglutide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are male or female not of childbearing potential * Have a body mass index of 23 to 50 kilograms per square meter (kg/m²), inclusive, at screening * Have had a stable body weight (\<5% body weight change) for the 3 months prior to screening * Have not modified their diet or ado...
LY3493269 is an investigational small molecule being studied for the treatment of type 2 diabetes mellitus. It is in Phase 1 clinical development and is not approved for any indication. Eli Lilly and Company is evaluating it in adults with type 2 diabetes.
LY3493269 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company is the sponsor of the clinical program evaluating this small molecule in type 2 diabetes.
LY3493269 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The Phase 1 program has completed one trial in participants with type 2 diabetes.
LY3493269 has been studied in one Phase 1 trial, NCT04515576, titled A Study of LY3493269 in Participants With Type 2 Diabetes. The trial was completed, enrolled 56 participants, was randomized, double-blind, and placebo-controlled, and was conducted in the United States.
Yes, LY3493269 - SC is an alternative name for LY3493269. Both names refer to the same investigational small molecule developed by Eli Lilly and Company for type 2 diabetes, so searches using either name point to the same asset.